Departement de Medecine, BrEAST Data Centre, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.
Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium.
Clin Cancer Res. 2015 Nov 1;21(21):4743-6. doi: 10.1158/1078-0432.CCR-14-3127.
Desmedt and colleagues published two articles, one in the June 1, 2007 issue, and the other in the August 15, 2008, issue of Clinical Cancer Research, that showed gene-expression signatures to be proliferation driven and time dependent, with their prognostic power decreasing with increasing follow-up years. Moreover, the articles showed that immune response is a crucial determinant of prognosis in the HER2-positive and estrogen receptor-negative/HER2-negative subtypes, providing a rationale to further explore the role of the antitumor immune response in these breast cancer subtypes.
德斯梅特及其同事发表了两篇文章，一篇发表于 2007 年 6 月 1 日，另一篇发表于 2008 年 8 月 15 日的《临床癌症研究》上，这些文章表明基因表达特征与增殖有关，且与时间相关，其预后能力随着随访年限的增加而降低。此外，这些文章表明，免疫反应是 HER2 阳性和雌激素受体阴性/HER2 阴性亚型预后的关键决定因素，这为进一步探索抗肿瘤免疫反应在这些乳腺癌亚型中的作用提供了依据。
